Tag: APVO436

May 10, 2018

Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and...
April 16, 2018

Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data...
March 13, 2018

Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today reported its financial results for...
June 7, 2017

Aptevo Therapeutics Presents Key Features of ADAPTIR

Aptevo Therapeutics revealed new information of its ADAPTIR protein therapeutic platform at two medical conferences.
April 3, 2017

Aptevo To Present New Data at Cancer Meeting

Aptevo Therapeutics announced the presentation of new clinical data for APVO436 and APVO437 at the upcoming American Association for Cancer...